Effect of Quetiapine on Negative Symptoms and Cognition

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-11-30

Study Completion Date

2003-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to investigate the outcome on negative symptoms of schizophrenic patients during therapy with quetiapine or risperidone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Comparison of Seroquel vs. Risperidone in Schizophrenia

NCT00034905

Schizophrenia

COMPLETED PHASE4

Quetiapine Extended Release Depression Symptoms

NCT00640562

Schizophrenia Depression

COMPLETED PHASE3

Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder

NCT00746421

Bipolar Disorder Cognitive Impairment

TERMINATED PHASE4

Quetiapine Induced Neuroplasticity in First-episode Schizophrenic Patients

NCT00554658

Schizophrenia

COMPLETED PHASE4

A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder

NCT03403790

Depression Bipolar Disorder

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Quetiapine fumarate

Intervention Type DRUG

Risperidone

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent
* men and women aged 18 to 65 years with diagnosis of schizophrenia
* score of at least 4 CGI, PANSS negative subscale score \> 21
* fulfil the criterion to be right-handed for inclusion in the fMRI investigations

Exclusion Criteria

* Substance or alcohol dependence
* female patients who are pregnant, lactating or at risk of pregnancy
* history of organic CNS-trauma, epilepsy, meningoencephalitis, psychosurgery, instable somatic conditions
* risk of suicide or aggressive behaviour
* history of electroconvulsive therapy, Parkinson's disease, Prolactin-dependent tumor

* existence of metal in the body as by cardiac pacemaker, coil, total prosthesis, metal splinter, metal articulation, metal balls.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No